LIMINATUS PHARMA INC (LIMN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.79+0.16%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · LIMN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of —
LIMN — private placement
Dated 2026-11-03
Entry into a Material Definitive Agreement. On November 2, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with a non-U.S. investor, pursuant to which such investor agreed to subscribe for, and the Company agreed to issue to such investor, an aggregate of 260,001 shares of the Company’s common stock (collectively, the “Shares”) in a private placement, at a purchase price of $2.50 per share for aggregate gross proceeds of $650,0…
Why it matters: Nasdaq closed the prior bid-price case after the share price stayed above $1.00 for 13 trading days. A new notice would put listing status back in focus.
Worry ifNasdaq sends a new notice after the closing bid price falls below $1.00 for 30 straight business days.
Less concerning ifNasdaq records no new bid-price notice, and the closing bid stays at or above $1.00.
Why it matters: Stockholder approval is needed before the new warrants can be used. If exercised, they add shares and bring in cash.
Watch forA company filing confirms stockholders approved the plan. The new warrants are then used for cash.
Also watch forStockholders reject the warrant plan, or the company reports it did not get approval.
Why it matters: The June warrant deal raised $1.9 million before costs. The company also said it may need more capital to fund its plans.
Worry ifThe Nov. 12 report says cash is low, or that more funding is needed to keep planned work going.
Less concerning ifThe Nov. 12 report gives cash and runway figures that cover planned work, with no near-term funding need stated.
Why it matters: These named cancer drug programs anchor the company’s stated pipeline. Clear progress would show that work is moving beyond capital and listing actions.
Supportive ifThe Nov. 12 report names a new study step, trial date, or other clear milestone for IBA101 or IBC101.
Worry ifThe report says a named program is paused, delayed, or dropped, or gives no milestone update.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$444 on $10,000 · ±4.4% | How much price usually moves either way. |
| Bad day | $1,246 loss on $10,000 · 12.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,754 loss on $10,000 · 97.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company used a 1-for-50 reverse split and a warrant deal to address listing and capital needs. Another such move may point to continued funding pressure.
Worry ifA new filing reports another reverse split, changes warrant prices, or ties funding to shares.
Less concerning ifThe company reports no new share-structure or warrant changes and gives a cash plan for its programs.